Ma, J., Song, Y., Shou, J., Bai, Y., Li, H., Xie, X., . . . Zhou, A. (2020). Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. Front Oncol.
Style de citation ChicagoMa, Jianhui, et al. "Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial." Front Oncol 2020.
Style de citation MLAMa, Jianhui, et al. "Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial." Front Oncol 2020.
Attention : ces citations peuvent ne pas être correctes à 100%.